| 摘要 |
The present invention relates to combinations of at least two components, component A and component B, component A being an immune checkpoint inhibitor, and component B being a pharmaceutically acceptable salt of the alkaline-earth radionuclide radium-223, the combination being useful for the treatment or prophylaxis of cancer. |
